Institute Gustave Roussy

Villejuif 98405

5 studies enrolling now · 12 studies all time

What they study most

AFP Expressing Tumors, Abdominal Neoplasm, Advanced Breast Cancer, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Melanoma, Advanced Solid Tumors, Breast Cancer Metastatic, Carcinoma, Endometrial Adenocarcinoma, Epstein-Barr Virus Infections, Genital Neoplasm, Female, Hepatocellular Cancer

Studies at this site

• A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma — Recruiting now
• A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) — Recruiting now
• A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements — Recruiting now
• A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) — Recruiting now
• A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors — Recruiting now
• AFPᶜ³³²T in Advanced HCC — Completed
• A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers — Completed
• Trial on Radical Upfront Surgery in Advanced Ovarian Cancer — Running, not enrolling
• Study to Evaluate CCS1477 in Advanced Tumours — Completed
• A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma — Completed
• MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer. — Completed
• EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer — Completed